Alexandra Hammond's questions to Bristol-Myers Squibb Co (BMY) leadership • Q4 2024
Question
Alexandra Hammond of Wolfe Research asked management to highlight the key pipeline assets they believe will drive revenue in the latter half of the decade, referring to them as their "favorite child or two."
Answer
CEO Christopher Boerner declined to pick a favorite, citing a "wealth of opportunity." He highlighted a first wave of major assets including Cobenfy, multiple CELMoD programs (iberdomide, mezigdomide, gocotomide), Milvexian, and LPA1. He also mentioned a next wave of assets, emphasizing the numerous potential catalysts expected over the next 24 months.